Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Non-Current Assets (2017 - 2025)

Cue Biopharma (CUE) has disclosed Non-Current Assets for 9 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 25.86% to $5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.2 million through Dec 2025, down 15.71% year-over-year, with the annual reading at $5.2 million for FY2025, 25.86% down from the prior year.
  • Non-Current Assets hit $5.2 million in Q4 2025 for Cue Biopharma, down from $5.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $15.7 million in Q2 2022 to a low of $5.2 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $10.5 million across 5 years, with a median of $10.0 million in 2021.
  • Biggest five-year swings in Non-Current Assets: crashed 33.97% in 2021 and later surged 69.37% in 2022.
  • Year by year, Non-Current Assets stood at $14.9 million in 2021, then fell by 5.6% to $14.1 million in 2022, then decreased by 28.52% to $10.1 million in 2023, then plummeted by 30.0% to $7.1 million in 2024, then dropped by 25.86% to $5.2 million in 2025.
  • Business Quant data shows Non-Current Assets for CUE at $5.2 million in Q4 2025, $5.8 million in Q3 2025, and $9.9 million in Q2 2025.